Vertex Pharmaceuticals Inc. closed 19.80% below its 52-week high of $519.88, which the company reached on November 8th.

Vertex Pharmaceuticals ( VRTX 3.06%) might be one of those special cases. Should you buy Vertex stock hand over fist before ...

Vertex Pharmaceuticals Inc. closed 18.39% short of its 52-week high of $519.88, which the company reached on November 8th.

Analysis of the S&P 500 health care sector's performance, quant ratings of top companies, and expert opinions on future ...

Vertex Pharmaceuticals (NASDAQ: VRTX) is a biotechnology company with a strong track record of success in developing ...

HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its ...

It can generate billions in revenue from both acute and possibly chronic pain. If approved, it would give Vertex ...

Along with its gene editing therapy Casgevy, Vertex is offering fertility preservation support for its patients—a program ...

A non-opioid painkiller from Vertex Pharmaceuticals could become a blockbuster, but questions remain on whether it will prove ...

J.P. Morgan analyst Jessica Fye has maintained their bullish stance on VRTX stock, giving a Buy rating today.Stay Ahead of the Market:Discover ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...

In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research ...